Hovione invests in filling for inhalable drugs

- Last updated on GMT

Related tags: Pharmacology

Hovione invests in filling for inhalable drugs
Hovione invests in filling for inhalable drugs
Hovione says demand drove acquisition of new capsule filling technology for inhalable drug products.

The Portugal-based firm installed a FlexaLAb filling system at its facility in Lisbon, explaining that the technology will support the production of drugs for Phase II and III trials but did not name the customer involved.

Company VP Peter Villax said: “We give our customers an edge in inhalation capsule filling for drug delivery to the lung, by providing access to a machine capable of very high precision filling of low doses, down to 5 mg.

We are perhaps the only independent company with expertise in every aspect of the inhaled drug development process and this acquisition strengthens our commitment to inhalation drug development​.”

The investment follow just over a year after Hovione added particle engineering capabilities to its contracting offering, initially through a technology investment​ and subsequently in partnership with Solvias​.

Related news

Show more

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars